

**PRESCRIPTION DRUG AFFORDABILITY BOARD MEETING**  
**Monday, May 19, 2025**  
**Minutes**

**AGENDA ITEM 1**

**Call Meeting to Order**

Chair Van Mitchell called the meeting to order at 2:03 p.m.

**Board Members present:** Van Mitchell, Gerard Anderson, Ph.D., Eberechukwu Onukwugha, MS, Ph.D., Joseph Levy, Ph.D., Stephen Rockower, MD

**AGENDA ITEM 2**

**Approval of minutes**

Chair Mitchell asked for a motion to approve the March 24, 2025 meeting minutes, the March 24, 2025 closed meeting minutes, and corrected January 27, 2025 meeting minutes as submitted. Dr. Anderson made the motion, which Dr. Levy seconded, and the Board unanimously approved the minutes.

**Action: Minutes APPROVED.**

**AGENDA ITEM 3**

**Opportunity for Public Comment**

The PDAB received seven written comments. These comments were shared with the Board and posted to the website. One comment received after the deadline that will be posted on the website and shared with the Board in accordance with the regulations. There were two requests for oral public comment.

1. Denise Gilmore, AFSCME Maryland, Council 3, Agenda Item 7: Cost Review Study
2. Erica Miller, public citizen, Agenda Item 7: Cost Review Study

**AGENDA ITEM 4**

**Budget Fee Assessment Update**

Dr. York gave a presentation summarizing FY25 fee assessment policies, results of the FY25 fee assessment to date, and plans moving forward. The staff did not recommend any changes to the fee assessment process or policies for FY26. The Board had the opportunity to ask questions and provide feedback.

## **AGENDA ITEM 5**

### **Administrative Update**

- Executive Director York provided an update on the Dossier Timeline and the Request for Information on the last two drugs. Staff plans to post both Farxiga and Jardiance Dossiers and provide a 15 day timeline for public comment.
- The next PDASC meeting is on June 23, 2025.
- The next PDAB meeting is July 28, 2025.
- Executive Director York provided a staffing and hiring update.

## **AGENDA ITEM 6**

### **Chair's Update**

Chair Mitchell did not have an update at this meeting.

## **AGENDA ITEM 7**

### **Cost Review Study**

#### **a. Staff Presentation—Cost Review Study Dossier (Farxiga)**

Dr. York provided a robust overview of the initial version of the Farxiga Dossier, including organization and attached exhibits. The Dossier consists of 8 different sections and these sections map to the regulatory elements. Executive Director York went through sections 4-8 today, as sections 1-3 were discussed at the March 24, 2025 Board meeting. The Board had the opportunity to ask questions and provide comments. This initial draft of the Farxiga Dossier is posted on the Board page of the website.

**b. Closed Session—To Consider and Discuss Confidential, Trade Secret and Proprietary Information, under GP § 3-305(b)(13) and HG 21-2c-03(e)(1)(iv) (Farxiga); and to Consult with Counsel and Receive Legal Advice Regarding the Cost Review Study, under GP § 3-305(b)(7).**

Chair Mitchell asked for a motion to close the session under General Provisions, § 3-305(b)(13) and § 3-305(b)(7), Annotated Code of Maryland, to consider and discuss confidential, trade secret and proprietary information and receive legal advice from counsel and maintain confidentiality and attorney client privilege in closed session.

Dr. Anderson moved to close the session and Dr. Rockower seconded the motion. All Board members voted to close the session; no member opposed the motion. Closed session commenced at 3:38 p.m. via Zoom breakout session.

### **SUMMARY OF CLOSED SESSION**

Pursuant to General Provisions, § 3-305(b)(13) and § 3-305(b)(7), Annotated Code of Maryland, on May 19, 2025 at 3:38 p.m. the Board met in closed session to receive advice of counsel regarding the procedures for performing the cost review study, and to discuss proprietary, trade secret and confidential information concerning Farxiga.

Van Mitchell, Dr. Onukwugha, Dr. Anderson, Dr. Rockower, Dr. Levy, Assistant Attorney General McDonald (counsel), Dr. York (Executive Director), and Zeid El-Kilani (regulatory economist) attended the closed session. AAG McDonald provided the Board with legal advice regarding the procedures for performing the cost review study. The Board reviewed and discussed certain proprietary, trade secret and confidential information concerning Farxiga. No actions and no votes were taken in the closed session.

### **AGENDA ITEM 8**

#### **Adjournment**

Chair Mitchell asked for a motion to adjourn the meeting. Dr. Levy made a motion to adjourn, which was seconded by Dr. Anderson.

**Adjourned** at 4:45 PM